Sponsored by
Latest
Topics
Topics
Accounting & Tax
Corporate Finance
Human Capital
Risk & Compliance
Strategy
Technology
Featured
Sustainability
5 Tips to Get Your Sustainability Story to the Stakeholders Who Matter
Sustainability reports are an important tool in a CFO’s strategic communications arsenal that helps attract employees, customers, and capital.
By
Leigh Ann Johnston
| January 30, 2023
Read More
Resources
CFO Live
2022 Survey
Sign Up
Menu
Topics
Accounting & Tax
Corporate Finance
Human Capital
Risk & Compliance
Strategy
Technology
Explore
Search
Latest
Resources
CFO Live
2022 Survey
Sign Up
Sponsored by
drugmaker
M&A
Gilead to Buy Cancer Drugmaker for $21 Billion
The acquisition of Immunomedics "represents significant progress in Gilead’s work to build a strong and diverse oncology portfolio."
By
Matthew Heller
| September 14, 2020
Read More
Risk & Compliance
J&J Speeds Up Timeline for Coronavirus Vaccine
After lagging behind other companies, J&J now expects to begin a late-stage study of its vaccine candidate in September.
By
Matthew Heller
| July 16, 2020
Read More
Credit & Capital
Akorn Files for Chapter 11 After Failed Takeover
The generic drugmaker listed $10 billion of debt and $10 billion of assets.
By
Lauren Muskett
| May 21, 2020
Read More
Strategy
Gilead to Invest $5B in Galapagos Partnership
The deal expands Gilead's investment in the European biotech as it seeks to add assets to its drug portfolio.
By
Matthew Heller
| July 15, 2019
Read More
M&A
Merck Agrees to Buy Peloton Therapeutics
The privately held cancer drugmaker had been set for a public offering Wednesday.
By
Lauren Muskett
| May 21, 2019
Read More
Financial Performance
Pfizer Beats Estimates on Strength in Key Drugs
Sales from Pfizer's innovative health division were particularly strong in the second quarter, with anti-smoking drug Chantix up 8% to $8.2 billion.
By
Matthew Heller
| July 31, 2018
Read More
Strategy
Shire Accepts Improved $62B Bid From Takeda
The deal is the largest-ever by a Japanese company and gives Takeda a lucrative portfolio of rare disease drugs.
By
Matthew Heller
| May 8, 2018
Read More
Strategy
Novartis to Buy AveXis in $8B Gene Therapy Bet
The deal gives the Swiss drugmaker a neurological disease treatment that may have "a multi-billion dollar peak sales potential."
By
Matthew Heller
| April 9, 2018
Read More
Strategy
Teva to Cut 14,000 Jobs in ‘Drastic’ Overhaul
The drugmaker says "there is no alternative" to its restructuring plan amid pricing pressure on its core generics business.
By
Matthew Heller
| December 14, 2017
Read More
People
Lilly Veteran Josh Smiley Promoted to CFO
Smiley takes over from Derica Rice amid a cost-cutting push aimed at freeing up cash for Lilly to invest in developing new drugs.
By
Matthew Heller
| October 2, 2017
Read More
Strategy
Alexion to Cut 20% of Workforce, Move HQ
The drugmaker is restructuring as it tries to rebuild its drug pipeline amid investigations of its sales practices.
By
Matthew Heller
| September 12, 2017
Read More
Strategy
Eli Lilly to Trim 3,500 Jobs to Save $500 Million
The drugmaker is seeking to become "a leaner, more nimble global organization" as it invests in a new generation of medicines.
By
Matthew Heller
| September 7, 2017
Read More